Vaxcyte (PCVX)
(Delayed Data from NSDQ)
$79.35 USD
+1.21 (1.55%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $79.24 -0.11 (-0.14%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Vaxcyte, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -402.27 | -223.49 | -100.08 | -89.22 | -50.27 |
Depreciation/Amortization & Depletion | -24.60 | 8.25 | 4.86 | 1.41 | 1.23 |
Net Change from Assets/Liabilities | 81.32 | 12.74 | -37.01 | 35.27 | 3.91 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 48.76 | 31.90 | 10.83 | 5.91 | -2.01 |
Net Cash From Operating Activities | -296.79 | -170.60 | -121.39 | -46.63 | -47.15 |
Property & Equipment | -16.06 | -5.84 | -6.53 | -1.11 | -1.20 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -705.43 | 80.43 | -205.78 | 0.00 | 0.00 |
Other Investing Activities | -51.82 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -773.31 | 74.59 | -212.31 | -1.11 | -1.20 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 552.95 | 765.11 | 3.90 | 1.05 | 0.44 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 267.31 | -0.28 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 86.87 | 96.44 | 13.90 | 106.51 | 41.40 |
Net Cash from Financing Activities | 639.81 | 861.55 | 17.80 | 374.87 | 41.57 |
Effect of Exchange Rate Changes | -6.69 | 0.14 | -0.44 | 0.09 | -0.34 |
Net Change In Cash & Equivalents | -436.97 | 765.67 | -316.34 | 327.22 | -7.11 |
Cash at Beginning of Period | 835.53 | 69.86 | 386.20 | 58.98 | 66.09 |
Cash at End of Period | 398.55 | 835.53 | 69.86 | 386.20 | 58.98 |
Diluted Net EPS | -4.14 | -3.44 | -1.93 | -3.02 | -13.25 |
Fiscal Year End for Vaxcyte, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -223.72 | -95.02 | -402.27 | -221.47 | -128.80 |
Depreciation/Amortization & Depletion | -14.36 | -7.90 | -24.60 | -25.18 | -13.09 |
Net Change from Assets/Liabilities | -81.63 | -73.83 | 81.32 | 43.26 | 9.27 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 39.19 | 17.63 | 48.76 | 35.41 | 22.19 |
Net Cash From Operating Activities | -280.52 | -159.12 | -296.79 | -167.98 | -110.43 |
Property & Equipment | -13.46 | -5.68 | -16.06 | -10.81 | -3.47 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -480.43 | -439.00 | -705.43 | -748.58 | -778.20 |
Other Investing Activities | -37.59 | -6.39 | -51.82 | 0.00 | 0.00 |
Net Cash from Investing Activities | -531.48 | -451.07 | -773.31 | -759.39 | -781.67 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 825.93 | 821.50 | 552.95 | 640.62 | 547.68 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 102.64 | -3.31 | 86.87 | -3.55 | 40.85 |
Net Cash from Financing Activities | 928.56 | 818.20 | 639.81 | 637.08 | 588.53 |
Effect of Exchange Rate Changes | 4.65 | 6.06 | -6.69 | 1.00 | -0.06 |
Net Change In Cash & Equivalents | 121.22 | 214.06 | -436.97 | -289.29 | -303.62 |
Cash at Beginning of Period | 398.55 | 398.55 | 835.53 | 835.53 | 835.53 |
Cash at End of Period | 519.77 | 612.62 | 398.55 | 546.24 | 531.90 |
Diluted Net EPS | -1.10 | -0.85 | -1.83 | -0.91 | -0.70 |